Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

02 Oct 2016 - 05 Oct 2016
10 Oct 2016 - 12 Oct 2016

Combined Spectroscopy System Rapidly Scans Skin Lesions for Cancer Signs

By Labmedica International staff writers
Posted on 18 Aug 2014
Print article
Image: The photo on the left shows the entire three-in-one spectroscopy system on an easily transportable utility cart. The right photo is a close-up of the probe (Photo courtesy of the University of Texas, Austin).
Image: The photo on the left shows the entire three-in-one spectroscopy system on an easily transportable utility cart. The right photo is a close-up of the probe (Photo courtesy of the University of Texas, Austin).
A team of biomedical engineers has designed an instrument for the rapid diagnosis of skin cancer that does not rely on examination of biopsy specimens.

Skin cancer is detected currently by examining biopsy specimens. However, statistics suggest that for every case of skin cancer detected there are roughly 25 negative biopsies performed. To correct this situation, investigators at the University of Texas, Austin (USA) combined three advanced spectroscopy instruments into a single tool for scanning skin lesions and detecting changes in the way that skin tissues interact with light when normal skin becomes cancerous with enlarged cell nuclei and disorganization of the uppermost layers of the skin.

The multimodal spectroscopy (MMS) device characterizes the tissue microenvironment via morphological changes observed through DRS (diffuse reflectance spectroscopy) and biochemical information via RS (Raman spectroscopy) and LIFS (laser-induced fluorescence spectroscopy).

The DRS measurement is a function of tissue scattering and absorption properties, which in turn are dependent upon tissue morphological changes. Therefore, analysis yields information about tissue blood fraction, oxygen saturation, tissue scattering coefficient, nuclear morphology, and collagen structure. LIFS is biochemically sensitive, as it interrogates endogenous fluorophores such as nicotinamide adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD), and collagen. Their fluorescence levels change with cancer progression that is associated with altered cellular metabolic pathways (NADH, FAD) or an altered structural tissue matrix (collagen). Raman spectroscopy exploits the inelastic scattering (so-called “Raman” scattering) phenomena to detect spectral signatures of important disease progression biomarkers, including lipids, proteins, and amino acids.

The spectroscopic and computer equipment required by the system fits onto a portable utility cart, and the probe is about the size of a pen. Each reading takes about 4.5 seconds to perform.

"Skin is a natural organ to apply imaging and spectroscopy devices to because of its easy access," said senior author Dr. James W. Tunnell, associate professor of biomedical engineering at the University of Texas, Austin. Most devices have been at the research stage for the last 10 years or so, but several are now undergoing clinical development. This probe that is able to combine all three spectral modalities is the next critical step to translating spectroscopic technology to the clinic."

A detailed description of the MMS device was published in the August 5, 2014, online edition of the journal Review of Scientific Instruments.

Related Links:
University of Texas, Austin


Print article
Sekisui Diagnostics

Channels

Industry News

view channel

Instrumentation Laboratory Acquires CA Casyso

Instrumentation Laboratory (IL) (Bedford, MA, USA), which manufactures instruments and reagents for the global hemostasis market, has acquired CA Casyso AG (Basel, Switzerland) and its Tem subsidiaries (Tem), a provider of in vitro diagnostic (IVD) testing for patient blood management (PBM). CA Casyso AG is the parent... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.